Antisense technology: an overview and prospectus.

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Molecular Medicine
• Drug Development

Background:

• Antisense oligonucleotide (ASO) technology targets RNA for disease treatment.
• Nine ASO drugs, spanning diverse chemical classes and administration routes, are currently approved.
• Nusinersen represents a significant commercial success in RNA-targeted therapeutics.

Purpose of the Study:

• To review key technological advancements driving progress in antisense oligonucleotide (ASO) therapy.
• To discuss clinical trial outcomes demonstrating the impact of these advances across various therapeutic areas.
• To provide perspectives on future strategic considerations and the trajectory of ASO development.

Main Methods:

• Analysis of approved antisense oligonucleotide (ASO) drugs and their characteristics (chemical class, mechanism, administration).
• Review of late- and middle-stage clinical development pipelines, focusing on applications for common diseases.
• Examination of recent clinical trial data to assess improvements in ASO potency, performance, and delivery.

Main Results:

• Significant progress in medicinal chemistry, molecular mechanism understanding, and targeted delivery has enhanced ASO potency and performance.
• ASOs in development are increasingly aimed at prevalent diseases, expanding therapeutic reach beyond rare conditions.
• Emerging ASO formulations include novel administration routes like aerosol and oral delivery, alongside new mechanisms of action.

Conclusions:

• Antisense oligonucleotide (ASO) technology is maturing, with approved drugs and promising candidates for a wide range of diseases.
• Technological innovations are crucial for improving ASO efficacy, safety, and applicability to broader patient populations.
• Strategic target selection and continued research into novel delivery and mechanisms will shape the future of ASO therapeutics.